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Background: Most bone tumors that occur in the clavicle are malignant. A few giant cell tumors (GCTs) of the
clavicle have been reported; however, the most appropriate operative method for this tumor has never been
discussed.
Case presentation: A 54-year-old man noticed enlargement of the proximal aspect of the right clavicle. A plain
X-ray revealed lytic change and ballooning of the proximal end of the right clavicle. The tumor was isointense on
T1-weighted magnetic resonance images and showed a mixture of low- and high-intensity areas on T2-weighted
images without extension to the surrounding soft tissues. Bone scintigraphy showed strong accumulation (normal/tumor
ratio, 2.31), and positron emission tomography revealed strong uptake of fluorine-18-2-fluoro-2-deoxy-d-glucose
(SUVmax, 6.0) in the proximal part of the right clavicle. Because we could not completely exclude malignancy, an
open biopsy was performed. Pathologically, the tumor comprised mononuclear stromal cells and multinuclear
giant cells, resulting in a diagnosis of a GCT of the bone. Although curettage may be considered for such lesions
(Campanacci grade II), we chose resection to minimize the chance of recurrence. The tumor was resected en-bloc with
the proximal half of the clavicle. No postoperative shoulder disproportion was observed, and full range of motion of
the right shoulder was maintained. The patient was satisfied with the surgical outcome (Musculoskeletal Tumor Society
score of 96 %). He returned to his original job as a land and house investigator without any signs of recurrence for 1 year
after surgery.
Conclusions: Although GCT of the bone rarely occurs in the clavicle, the typical X-ray findings demonstrated
in the present case are helpful for a correct diagnosis. Although en-bloc resection without reconstruction is
appropriate for GCTs in expendable bones, there has been much discussion about shoulder function after total
claviculectomy. Considering the importance of the function of the clavicle, which is to support the scapula
through the acromioclavicular joint, we preserved the muscle attachments of the deltoid, trapezius, and pectoralis
major. Because both the oncological and functional outcomes were satisfactory, we recommend preservation of as
much of the clavicle as possible in patients with clavicular bone tumors.
Keywords: Giant cell tumor, Claviculectomy, Pathology, Shoulder function* Correspondence: naga@m2.kufm.kagoshima-u.ac.jp
1Department of Orthopaedic Surgery Graduate School of Medical and Dental
Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520,
Japan
Full list of author information is available at the end of the article
© 2015 Nagano et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Nagano et al. BMC Musculoskeletal Disorders  (2015) 16:142 Page 2 of 6Background
Giant cell tumors (GCTs) are aggressive bone tumors
comprising osteoclast-like multinuclear cells and hyper-
plastic mononuclear interstitial cells. In the latest classifi-
cation of bone tumors by the World Health Organization,
GCTs are classified as “intermediate locally aggressive,
rarely metastasizing” tumors [1]. Because GCTs show clin-
ically “uncertain behavior” and have a relatively high re-
currence rate, the surgical method should be carefully
chosen based on the radiographic classification proposed
by Campanacci et al. [2]. Sites often affected by GCTs are
the distal femur, proximal tibia, and distal radius; GCTs
rarely occur in the clavicle [3]. Errani et al. [4] found no
GCTs arising in the clavicula among 349 GCTs of bone.
However, the national bone tumor registry in Japan re-
ported two cases of GCTs in the clavicula (1.1 %) from
2006 to 2012 [5]. Although bone tumors rarely occur in
the clavicle, a high proportion of those that develop at this
site are malignant [6, 7]. Therefore, establishing a list of
preoperative differential diagnoses of bone tumors involv-
ing the clavicles is often difficult. Because the clavicle is a
non-weight-bearing bone and is functionally expendable,
the optimal surgical resection method for GCTs in this
area is controversial. We herein present a case of a GCT
in the proximal clavicle. Biopsy was performed to reach a
pathological diagnosis after performance of imaging stud-
ies, including radionuclide scanning. Functional evaluation
after proximal partial claviculectomy demonstrated satis-
factory results.
This case has been reported in accordance with the
Helsinki Declaration. This retrospective case report is an
exemption by the ethics committee of Kagoshima
University.
Case presentation
A 54-year-old man noticed enlargement of the proximal
aspect of the right clavicle. He made an appointment to
undergo positron-emission tomography (PET)-based
cancer screening 1 month later, which revealed a lesion
with abnormal accumulation in the right clavicle. He
was referred to our department for further examination.
Plain X-ray revealed lytic change and ballooning of the
proximal end of the right clavicle (Fig. 1a). Computed
tomography (CT) showed an expanded medullary cavity
and thinning of the cortex without periosteal reaction
(Fig. 1b). No lung metastasis was demonstrated by thin-
slice chest CT. The tumor was isointense on T1-weighted
magnetic resonance images and showed a mixture of low-
and high-intensity areas on T2-weighted images. However,
the tumor did not extend to the surrounding soft tissues
(Fig. 1c–e). Bone scintigraphy showed uptake of 99mTc-
methylene diphosphonate in the proximal clavicle (Fig. 2a),
and thallium-201 scintigraphy showed strong accumula-
tion (normal/tumor ratio, 2.31), suggesting an abundantblood supply to the tumor (Fig. 2b). PET revealed
strong accumulation of fluorine-18-2-fluoro-2-deoxy-d-
glucose (SUVmax, 6.0) in the proximal part of the right
clavicle, but no other primary cancer or metastases
were demonstrated in other sites of the body (Fig. 2c).
All hematological tumor markers (CA19-9, CEA, AFP,
NSE, IL-2R, urinary Bence-Jones protein, and serum
M-protein) were negative.
Based on the characteristic roentgenographic and CT
imaging findings with ballooning of the affected bone,
the primary differential diagnosis was a GCT. However,
we could not completely exclude malignancy because of
the affected site, patient age, and degree of accumulation
on PET. We thus performed an open biopsy of the
tumor. Preoperative angiography was performed to pre-
vent dissemination due to massive perioperative bleeding;
however, large nutrient vessels requiring embolization
were not demonstrated. Fragile, yellowish-brown tumor
tissue was obtained by the biopsy (Fig. 3a). Pathologically,
the tumor comprised mononuclear stromal cells and mul-
tinuclear giant cells (Fig. 3b). The stromal cells showed
oval nuclei with fine, uniform chromatin, and nucleoli
were frequently found (Fig. 3c). Many multinucleated
giant cells resembling osteoclasts were surrounded by
mononuclear cells (Fig. 3c). The case was pathologically
diagnosed as a GCT of bone, and surgical treatment was
planned.
Because this was determined to be a grade II tumor
(cortical erosion, deformity, and expansion of bone) ac-
cording to the Campanacci classification [2], curettage
was considered initially. However, we chose resection to
minimize the chance of recurrence because adhesion be-
tween the clavicle and major vessels was anticipated,
which would make reoperation very difficult. Addition-
ally, the clavicle does not necessarily require reconstruc-
tion after resection, and this patient was not engaged in
physical work. An osteotomy was performed 8 cm from
the proximal edge of the clavicle (Fig. 4b), and the ster-
noclavicular joint was then disarticulated (Fig. 4c). The
tumor was resected en-bloc with half of the clavicle. It
contained a thin, fragile cortex, but extension to the sur-
rounding soft tissue was absent (Fig. 4d). The residual
clavicular length was 7.5 cm on postoperative roentgen-
ography (Fig. 4e), and no displacement of the resection
edge of the clavicle was observed (Fig. 4f ).
No shoulder disproportion was observed postoperatively
(Fig. 5a). The range of motion of the right shoulder was
normal (Fig. 5b), and the Japanese Orthopaedic Associ-
ation shoulder score (JOA score) [8] was 99 points.
The patient was satisfied with the surgical outcome,
and the Musculoskeletal Tumor Society score [9] was
96 %. He returned to his original job as a land and
house investigator without any signs of recurrence for
1 year after surgery.
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Fig. 2 Radionuclear medicine. (a) Bone scintigraphy showed marked uptake in the proximal clavicle, and (b) thallium-201 scintigraphy showed
strong accumulation (normal/tumor ratio, 2.31), suggesting an abundant blood supply to the tumor. (c) Positron-emission tomography demonstrated
strong accumulation of fluorine-18-2-fluoro-2-deoxy-d-glucose (SUVmax, 6.0) in the proximal part of the right clavicle, but there were no




Fig. 1 Plain X-ray, computed tomography, and magnetic resonance imaging of the right clavicle. (a) Plain X-ray showed lytic change and ballooning
of the proximal end of the right clavicle. (b) Computed tomography (CT) demonstrated an expanded medullary cavity and thinning of the cortex
without periosteal reaction. (c, d) 3D-CT angiography images demonstrated proximity of the subclavian artery (arrow) and the tumor. The tumor
showed (e) isointensity on T1-weighted images and (f) a mixture of low- and high-intensity areas on T2-weighted images. (g) The tumor tissue was
significantly enhanced by gadolinium; however, the tumor did not extend to the surrounding soft tissues
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Fig. 3 Macroscopic and microscopic biopsy findings. (a) Fragile, yellowish-brown tumor tissue was obtained by the biopsy. (b) Pathologically, the
tumor comprised mononuclear stromal cells and multinuclear giant cells (original magnification, ×100). (c) The stromal cells showed oval nuclei with
fine, uniform chromatin, and nucleoli were frequently found (original magnification, ×200). Many multinucleated giant cells resembling osteoclasts were
surrounded by mononuclear cells (arrows)
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Dahlin et al. [7] reported that in their study, more than
90 % of bone tumors that occurred in the clavicle were
malignant. Other authors have reported high malignancy
rates of 51 to 66 % [10, 11], suggesting that physicians
should consider the presence of malignancy when a
bone tumor is suspected in the clavicle. In a recent
large-scale report by Ren et al. [6], the benign/malignant
ratio was 1.34 among 206 clavicle-origin bone tumors.
In the current case, characteristic roentgen imaging find-
ings were suggestive of a GCT; however, the possibility
of malignancy could not be completely excluded because
of the imaging findings, including PET, and the rare site
of origin. It is known that malignant bone tumors show
a high SUVmax in PET. Aoki et al. [12] reported an
average SUVmax of 2.2 ± 1.5 and 4.3 ± 3.2 in benign and
malignant bone tumors, respectively. GCT of bone, a
relatively aggressive bone tumor, shows a high SUV. The
average SUV of GCT (4.6 ± 1.1) is reportedly not signifi-
cantly different from that of osteosarcoma (3.1 ± 1.0)
[12]. Preoperative chemotherapy should be considered
for malignant bone tumors, including osteosarcoma,
Ewing’s sarcoma, and plasmacytoma, and we believe that
biopsy should be considered in cases characterized by
aggressive behavior. Although the present patient first
underwent PET/CT examination by his own choice,
this is not a recommended diagnostic procedure for
bone tumors in the clavicula. As Rossi et al. [13] de-
scribed in their recent review of six cases of clavicular
bone tumors, plain X-rays, MRI, and total body CTscans are crucial for the diagnosis and staging of cla-
vicular tumors.
A principal surgical treatment method for GCTs,
which are benign bone tumors, is curettage. However,
the relatively high local recurrence rate (>20 %) is a
problem [3, 14, 15]. Various adjuvant treatments, such
as liquid nitrogen, ethanol, phenol, and hydrogen perox-
ide, have been used to reduce the recurrence rate [3, 15].
However, recurrence cannot be completely suppressed,
even with the use of adjuvant therapy. Rather, complete
removal of the tumor tissue is important. It should also
be kept in mind that GCT is associated with a risk of
lung metastasis (2 %) [3, 15], and this risk may increase
with local recurrence [1]. Most surgeons, including us,
mainly perform extensive curettage using a high-speed
burr or argon beam coagulator followed by polymethyl
methacrylate (PMMA) cementing. The advantages of
PMMA cementing are reconstruction of the defect,
which allows for immediate weight-bearing, and the ease
of identifying recurrence because of the clear border be-
tween the PMMA and host bone [3, 15]. In contrast, en-
bloc resection should be considered in grade III cases
characterized by cortical bone destruction and a soft tis-
sue mass. However, subsequent reconstruction, which
sometimes requires a bulky tumor prosthesis, is often
problematic [14]. In contrast, en-bloc resection without
any reconstruction is performed for GCTs in expendable
bones such as the distal ulna, proximal fibula, or iliac
wing. Because there are only a few reports of clavicular
GCTs [16–19], the optimal surgical method has not
ba
Fig. 5 Postoperative appearance and range of motion. (a) Disproportion






Fig. 4 Intraoperative findings. (a) In the supine position with the right arm abducted, the right clavicle was carefully exposed without damaging
the tumor capsule. (b) An osteotomy was made 8 cm from the proximal edge of the clavicle (arrows). (c) Disarticulation of the sternoclavicular
joint was then performed. (d) The tumor, resected en-bloc with half of the clavicle, had a thin, fragile cortex, but no extension to the soft tissue.
(e) The residual clavicular length was 7.5 cm on postoperative roentgenography. (f) No displacement of the resection edge of the clavicle was observed
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omy, either partial or total, might be a good option for
clavicular GCTs. Although partial claviculectomy was
chosen in the present case, extensive curettage and
PMMA cementing may be considered for younger pa-
tients with higher physical activity.
Whether a clavicular bone tumor is malignant or be-
nign is key to selecting the most appropriate surgical
method. Obviously, total claviculectomy will be per-
formed for malignant bone tumors [11, 20]. However,
postoperative functional loss and risk of recurrence asso-
ciated with resection should be taken into consideration
when selecting the operative method for benign tumors,
whether GCTs or other bone tumors. There has been
much discussion about shoulder function after total
clavicle resection. Krishnan et al. [21] reported that the
postoperative function of the affected limb was normal
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lectomy. In contrast, Rockwood and Wirth [22] reported
unsatisfactory outcomes in most cases (85 %) because of
pain, loss of muscle strength, and dropping of the shoul-
der with or without neurovascular compression or
shoulder joint instability; they therefore recommended
that surgeons preserve as much of the clavicle as possible.
An important function of the clavicle is support of the
scapula through the acromioclavicular joint. Muscles such
as the deltoid, trapezius, and pectoralis major also attach
in this region and serve as a site of action. We resected
the proximal clavicle with a margin of 2 cm from the
tumor edge, preserving 7.5 cm of the distal clavicle, and
were able to maintain a portion of its normal function as
described above. Therefore, surgeons should consider how
much of the distal part of the clavicle they can preserve to
avoid its proximal displacement, which may induce pain
or cosmetic issues.
In conclusion, GCT should be considered when the typ-
ical X-ray appearance is observed in a patient with an ag-
gressive clavicular bone tumor. If partial resection of the
clavicle is necessary, we recommend preservation of as
much of the clavicle as possible because no asymmetry,
pain, or shoulder imbalance occurred in the present case.
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